Arch Neurol Chicago
-
Arch Neurol Chicago · Jan 2005
Randomized Controlled Trial Comparative Study Clinical TrialIntermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.
Prednisone treatment is used to prolong ambulation in patients with Duchenne muscular dystrophy (DMD). However, since severe adverse effects often accompany prednisone treatment, it is debatable whether the benefits of prednisone treatment outweigh its adverse effects. ⋯ Prednisone slowed deterioration of muscle function and muscle force in ambulant patients with DMD. Although adverse effects were present, patient quality of life was not affected. Therefore, short-term prednisone treatment can be recommended to preserve motor functions in ambulant patients with DMD.
-
Arch Neurol Chicago · Apr 2004
Randomized Controlled Trial Multicenter Study Clinical TrialTopiramate in migraine prevention: results of a large controlled trial.
Open-label trials and small controlled studies report topiramate's efficacy in migraine prevention. ⋯ Topiramate, 100 or 200 mg/d, was effective as a preventive therapy for patients with migraine.
-
Arch Neurol Chicago · Jul 2003
Randomized Controlled Trial Clinical TrialA randomized trial of amantadine in Huntington disease.
Huntington chorea, like levodopa-induced dyskinesias, may be responsive to amantadine hydrochloride treatment. ⋯ Elbow proprioception was not shown to be related to Huntington chorea. Amantadine hydrochloride treatment at doses of 300 mg/d had no effect, on average, for Huntington chorea, although most patients felt subjectively better during the short course of amantadine treatment.
-
Arch Neurol Chicago · Jun 2003
Randomized Controlled Trial Clinical TrialAnalysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Treatment with cholinesterase inhibitors improves cognition in patients with Alzheimer disease (AD). In studies designed with a washout period at the end of the study, after treatment with a cholinesterase inhibitor is discontinued, the cognitive benefits of therapy are no longer apparent following washout. The rivastigmine trials discussed in this article were not designed with a posttreatment washout period at the end of the study. Therefore, to evaluate the effect of discontinuing treatment, we analyzed the retrieved dropout (RDO) population. ⋯ After discontinuation of therapy, rivastigmine-treated patients exhibited less deterioration in cognitive function compared with placebo-treated patients. The less severe worsening of cognition after withdrawal of treatment in patients previously treated with rivastigmine suggests an effect on disease progression.
-
Arch Neurol Chicago · Oct 2002
Randomized Controlled Trial Multicenter Study Clinical TrialEffects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Parkinson disease (PD) is a degenerative neurological disorder for which no treatment has been shown to slow the progression. ⋯ Coenzyme Q10 was safe and well tolerated at dosages of up to 1200 mg/d. Less disability developed in subjects assigned to coenzyme Q10 than in those assigned to placebo, and the benefit was greatest in subjects receiving the highest dosage. Coenzyme Q10 appears to slow the progressive deterioration of function in PD, but these results need to be confirmed in a larger study.